Crinetics Pharmaceuticals (CRNX)

KSIX Media Holdings, Inc., Mar Ked Mineral Exploration, Inc., NORTH AMERICAN ENERGY RESOURCES, INC., North American Energy Resources, Inc., Surge Holdings, Inc.

SEC CIK

0001658247

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

CRNX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$76.83

Low target

$40.00

High target

$143.00

Latest filings (excl ownership)

View all

6 Nov 25

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results

6 Nov 25

8-K

Crinetics Announces FDA Approval of PALSONIFYTM (paltusotine) for the Treatment of Adults with Acromegaly

7 Aug 25

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results

7 Aug 25

8-K

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

30 Jun 25

8-K

Regulation FD Disclosure

26 Jun 25

8-K

Submission of Matters to a Vote of Security Holders

12 Jun 25

DEFA14A

Additional proxy soliciting materials

8 May 25

Transcripts

View all

CRNX

Earnings call transcript

2025 Q3

6 Nov 25

CRNX

Earnings call transcript

2025 Q2

7 Aug 25

CRNX

Earnings call transcript

2024 Q4

27 Feb 25

CRNX

Earnings call transcript

2024 Q3

12 Nov 24

CRNX

Earnings call transcript

2024 Q2

8 Aug 24

CRNX

Earnings call transcript

2024 Q1

9 May 24

CRNX

Earnings call transcript

2023 Q4

28 Feb 24

CRNX

Earnings call transcript

2020 Q4

31 Mar 21

Latest ownership filings

View all

Dana Pizzuti

3 Dec 25

144

Notice of proposed sale of securities

1 Dec 25

SCHEDULE 13G/A

Beneficial ownership report (amended)

Notice of proposed sale of securities

Notice of proposed sale of securities

1 Oct 25

Richard Scott Struthers

Notice of proposed sale of securities

26 Sep 25

Financial summary

Financial statements Chart CRNX financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	112.20 mm	112.20 mm	112.20 mm	112.20 mm	112.20 mm	112.20 mm
Cash burn (monthly)	(no burn)	17.20 mm	47.53 mm	39.82 mm	36.91 mm	28.97 mm
Cash used (since last report)	n/a	37.23 mm	102.89 mm	86.20 mm	79.89 mm	62.72 mm
Cash remaining	n/a	74.97 mm	9.31 mm	26.00 mm	32.31 mm	49.48 mm
Runway (months of cash)	n/a	4.4	0.2	0.7	0.9	1.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CRNX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	246	234	+5.1%
Opened positions	38	28	+35.7%
Closed positions	26	29	-10.3%
Increased positions	110	94	+17.0%
Reduced positions	65	74	-12.2%

13F shares	Current	Prev Q	Change
Total value	4.60 tn	3.87 tn	+19.1%
Total shares	101.40 mm	86.23 mm	+17.6%
Total puts	11.70 k	44.20 k	-73.5%
Total calls	26.10 k	23.30 k	+12.0%
Total put/call ratio	0.4	1.9	-76.4%

Largest owners	Shares	Value	Change
Vanguard	9.09 mm	$464.74 bn	+44.6%
FMR	8.93 mm	$456.49 bn	+100.4%
BlackRock	7.52 mm	$384.25 bn	+14.7%
Wellington Management	6.95 mm	$355.38 bn	+55.9%
Driehaus Capital Management	6.14 mm	$313.99 bn	+4.3%
T. Rowe Price	5.41 mm	$276.84 mm	+9.5%
EcoR1 Capital	4.29 mm	$219.25 bn	0.0%
Farallon Capital Management	4.08 mm	$208.36 bn	+250.7%
STT State Street	2.99 mm	$152.92 bn	+5.4%
JHG Janus Henderson	2.80 mm	$142.90 bn	+15.1%

Largest transactions	Shares	Bought/sold	Change
FMR	8.93 mm	+4.47 mm	+100.4%
Farallon Capital Management	4.08 mm	+2.91 mm	+250.7%
Vanguard	9.09 mm	+2.80 mm	+44.6%
Wellington Management	6.95 mm	+2.49 mm	+55.9%
BlackRock	7.52 mm	+965.25 k	+14.7%
Paradigm Biocapital Advisors	1.91 mm	-605.92 k	-24.1%
Perceptive Advisors	184.53 k	-540.17 k	-74.5%
SG Americas Securities	542.45 k	+529.48 k	+4084.6%
UBS UBS	707.73 k	+524.84 k	+287.0%
Point72 Asset Management	2.79 mm	+488.30 k	+21.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRNX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Dec 25	Dana Pizzuti	Common Stock	Sell	Dispose S	No	Yes	45.02	5,000	225.10 k	66,837
1 Dec 25	Dana Pizzuti	Common Stock	Option exercise	Acquire M	No	No	16.89	5,000	84.45 k	71,837
1 Dec 25	Dana Pizzuti	Stock Option Common Stock	Option exercise	Dispose M	No	No	16.89	5,000	84.45 k	69,042
3 Nov 25	Dana Pizzuti	Common Stock	Sell	Dispose S	No	Yes	43.27	100	4.33 k	66,270
3 Nov 25	Dana Pizzuti	Common Stock	Sell	Dispose S	No	Yes	42.65	4,900	208.99 k	66,370
3 Nov 25	Dana Pizzuti	Common Stock	Option exercise	Acquire M	No	No	16.89	5,000	84.45 k	71,270
3 Nov 25	Dana Pizzuti	Stock Option Common Stock	Option exercise	Dispose M	No	No	16.89	5,000	84.45 k	74,042
1 Oct 25	Dana Pizzuti	Common Stock	Sell	Dispose S	No	Yes	41.81	5,000	209.05 k	66,270
1 Oct 25	Dana Pizzuti	Common Stock	Option exercise	Acquire M	No	No	16.89	5,000	84.45 k	71,270
1 Oct 25	Dana Pizzuti	Stock Option Common Stock	Option exercise	Dispose M	No	No	16.89	5,000	84.45 k	79,042